World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
61
Citations
13034
World Ranking
11374
National Ranking
202

Overview

Christoph Driessen is affiliated with the University of St. Gallen in Switzerland. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, their work delves deeply into subfields including Molecular Biology, Hematology, Oncology, Immunology, and Genetics.

The scientist's main research topics encompass multiple aspects of hematologic cancers and treatment strategies, notably:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Ubiquitin and Proteasome Pathways
  • Peptidase Inhibition and Analysis
  • Immunotherapy and Immune Responses
  • Chronic Lymphocytic Leukemia Research
  • CAR-T Cell Therapy Research

Frequent coauthors working alongside Christoph Driessen include Lenka Bešše, Andrej Bešše, Hermann Einsele, Mario Boccadoro, and Pieter Sonneveld, with collaborative publications ranging from 22 to 38 papers each.

The scientist's publications are regularly featured in several prominent journals, with the highest number of contributions appearing in Blood, followed by Clinical Lymphoma Myeloma & Leukemia, Cancer Research, Leukemia, and HemaSphere.

Selected recent papers authored or coauthored by Christoph Driessen include:

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021, The Lancet Oncology
  • Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2020, Leukemia
  • Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network, 2023, The Lancet Oncology
  • The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance, 2022, Nature Communications

Best Publications

  • Autophagy promotes MHC class II presentation of peptides from intracellular source proteins

    Jörn Dengjel;Oliver Schoor;Rainer Fischer;Michael Reich

  • Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4

    Zdenek Skrott;Martin Mistrik;Klaus Kaae Andersen;Søren Friis

  • Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

    Shirin Arastu-Kapur;Janet L. Anderl;Marianne Kraus;Francesco Parlati

  • Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

    Fiamma Berner;David Bomze;Stefan Diem;Omar Hasan Ali

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michele Cavo;Meral Beksac;Lucia Pantani

  • Proteases involved in MHC class II antigen presentation.

    Jose A. Villadangos;Rebecca A. R. Bryant;Jan Deussing;Christoph Driessen

  • Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages

    Guo-Ping Shi;Rebecca A.R. Bryant;Richard Riese;Steven Verhelst

  • Multiple myeloma: patient outcomes in real-world practice.

    Kwee Yong;Michel Delforge;Christoph Driessen;Leah Fink

  • Cathepsin S Controls the Trafficking and Maturation of Mhc Class II Molecules in Dendritic Cells

    Christoph Driessen;Rebecca A.R. Bryant;Ana-Maria Lennon-Duménil;José A. Villadangos

  • European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

    Monika Engelhardt;Evangelos Terpos;Martina Kleber

  • Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

    Holger Schulz;Ute Rehwald;Franck Morschhauser;Thomas Elter

  • Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)

    Christoph Mamot;Dirk Klingbiel;Felicitas Hitz;Christoph Renner

  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

    Philippe Moreau;Shaji K. Kumar;Jesús San Miguel;Faith Davies

  • Treatment of relapsed CD20 + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

    Ute Rehwald;Holger Schulz;Marcel Reiser;Markus Sieber

  • Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.

    T Rückrich;M Kraus;J Gogel;A Beck

  • Induction of cytokines by zinc ions in human peripheral blood mononuclear cells and separated monocytes.

    C Driessen;K Hirv;L Rink;H Kirchner

  • Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis

    Eva Tolosa;Weijie Li;Yoshiyuki Yasuda;Wolfgang Wienhold

  • Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.

    G P Soriano;L Besse;N Li;M Kraus

  • Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro

    Hermann Beck;Gerold Schwarz;Christian J. Schröter;Martin Deeg

  • Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

    Omar Hasan Ali;Fiamma Berner;David Bomze;Mirjam Fässler

Frequent Co-Authors

Herman S. Overkleeft
Herman S. Overkleeft Leiden University
Michele Cavo
Michele Cavo University of Bologna
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Hubert Kalbacher
Hubert Kalbacher University of Tübingen
Heinz Ludwig
Heinz Ludwig University of Vienna
Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Roman Hájek
Roman Hájek University of Ostrava
Mario Boccadoro
Mario Boccadoro University of Turin
Hermann Einsele
Hermann Einsele University of Würzburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry opens doors to a range of rewarding career and education options in the health and life sciences. If you’re interested in the administrative side of healthcare, the job outlook for medical billing and coding shows promising growth, with strong demand for skilled professionals.

For those seeking flexibility and affordability, consider earning an online health information management degree. This field combines healthcare, business, and technology to support patient care and hospital operations.

Nutrition is another promising pathway. Pursuing the cheapest online master's in nutrition allows you to upskill in nutrition science and opens doors to roles in wellness, clinical practice, and research.

Lastly, hands-on healthcare roles such as sonography are highly regarded and in demand. Accredited online sonography programs are available for those wanting to become ultrasound techs, offering both flexibility and specialized training.

Best Scientists Citing Christoph Driessen

Trending Scientists